Il topiramato nel trattamento dell'epilessia farmacoresistente: Risultati di uno studio a lungo termine

R. Michelucci; D. Passarelli; M. Di Fazio; C. A. Tassinari

Il topiramato nel trattamento dell'epilessia farmacoresistente: Risultati di uno studio a lungo termine

Translated title of the contribution: Topiramate in the treatment of drug-resistant epilepsy: A long-term follow-up study

R. Michelucci, D. Passarelli, M. Di Fazio, C. A. Tassinari

Istituto Scienze Neurologiche

Research output: Contribution to journal › Article › peer-review

Abstract

We investigated the long-term efficacy and tolerability of add-on Topiramate, used under placebo- controlled conditions, in 13 adult refractory epileptic patients, mostly with complex partial seizures. Overall, 4 patients (33%) were still on Topiramate (400 to 1000 mg/daily) after a mean period of 30 months. CNS-related side effects occurred in 10 patients and were usually transitory and mild. We conclude that Topiramate maintains its benefit on long-term follow-up in one third of the patients initially exposed to the study drug.

Translated title of the contribution	Topiramate in the treatment of drug-resistant epilepsy: A long-term follow-up study
Original language	Italian
Pages (from-to)	255-256
Number of pages	2
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	95-96
Publication status	Published - 1996

ASJC Scopus subject areas

Clinical Neurology

Cite this

@article{a310a7a2b9904284b584d38603195e92,

title = "Il topiramato nel trattamento dell'epilessia farmacoresistente: Risultati di uno studio a lungo termine",

abstract = "We investigated the long-term efficacy and tolerability of add-on Topiramate, used under placebo- controlled conditions, in 13 adult refractory epileptic patients, mostly with complex partial seizures. Overall, 4 patients (33%) were still on Topiramate (400 to 1000 mg/daily) after a mean period of 30 months. CNS-related side effects occurred in 10 patients and were usually transitory and mild. We conclude that Topiramate maintains its benefit on long-term follow-up in one third of the patients initially exposed to the study drug.",

keywords = "Long-term follow-up, Refractory epilepsy, Topiramate",

author = "R. Michelucci and D. Passarelli and {Di Fazio}, M. and Tassinari, {C. A.}",

year = "1996",

language = "Italian",

pages = "255--256",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "95-96",

}

TY - JOUR

T1 - Il topiramato nel trattamento dell'epilessia farmacoresistente

T2 - Risultati di uno studio a lungo termine

AU - Michelucci, R.

AU - Passarelli, D.

AU - Di Fazio, M.

AU - Tassinari, C. A.

PY - 1996

Y1 - 1996

N2 - We investigated the long-term efficacy and tolerability of add-on Topiramate, used under placebo- controlled conditions, in 13 adult refractory epileptic patients, mostly with complex partial seizures. Overall, 4 patients (33%) were still on Topiramate (400 to 1000 mg/daily) after a mean period of 30 months. CNS-related side effects occurred in 10 patients and were usually transitory and mild. We conclude that Topiramate maintains its benefit on long-term follow-up in one third of the patients initially exposed to the study drug.

AB - We investigated the long-term efficacy and tolerability of add-on Topiramate, used under placebo- controlled conditions, in 13 adult refractory epileptic patients, mostly with complex partial seizures. Overall, 4 patients (33%) were still on Topiramate (400 to 1000 mg/daily) after a mean period of 30 months. CNS-related side effects occurred in 10 patients and were usually transitory and mild. We conclude that Topiramate maintains its benefit on long-term follow-up in one third of the patients initially exposed to the study drug.

KW - Long-term follow-up

KW - Refractory epilepsy

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=0030410940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030410940&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0030410940

SP - 255

EP - 256

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 95-96

ER -

Il topiramato nel trattamento dell'epilessia farmacoresistente: Risultati di uno studio a lungo termine

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this